FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE

FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE July 24, 2018 What if a patient could use her own cells to treat her disease? Bench-to-bedside therapeutics are possible with cell and gene therapies, and there has been steady growth in these industries over the past few years. According to the Alliance of Regenerative […]

Read More

Ask DEL BioPharma LLC: Selecting a CRO/CMO involves multiple considerations that are applicable to any component of the drug discovery/development process.  From the perspective of API manufacturing, it is critical to understand the following:

A company is looking to build a partnership with a CRO for the development of a new drug. This decision is a complex one and can play a significant role in the success for the company. What are the top 3 considerations that the company must make in their selection process to ensure that they […]

Read More

Bead-beating tissue homogenisation technology – a powerful and high throughput sample prep tool for quantitation of analyte in bone, skin & lymph node

Bead-beating tissue homogenisation technology – a powerful and high throughput sample prep tool for quantitation of analyte in bone, skin & lymph node Bhavesh Patel, Director – Head DMPK-Bioanalysis, Eurofins Advinus Limited, BhaveshPatel3@eurofins.com Estimation of drug concentrations in tough tissues such as skin, lymph nodes, ocular tissues and bones is critical for many preclinical pharmacokinetic studies. For […]

Read More

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc. $133 Million Deal Adds European Early Development Center of Excellence to Global Network   SOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has […]

Read More

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development   SOMERSET, N.J. – July 10, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Berkeley Lights, Inc. (BLI), a leader in digital cell biology, today announced […]

Read More

China’s CROs Make Connection in S.D. #BiocomCRO

PHARMA: THEY’RE PART OF GROWING BIOTECH RELATIONSHIP China’s CROs Make Connection in S.D. By Jared Whitlock Sunday, June 10, 2018   San Diego — In San Diego, the last decade gave rise to biotechs farming out work to contract research organizations, or CROs. It’s an industry increasingly colored by China. In recent years, Chinese-linked CROs, led by […]

Read More

Catalent Biologics Supports InterveXion on New Treatment for Methamphetamine Users

SOMERSET, N.J. – May 31, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200. STAMPOUT will […]

Read More